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allograft dysfunction is uncertain. It is presumed that
the pathogenesis of BOS has an immunologic basis and
that BOS is a manifestation of chronic rejection.
Objective: A retrospective analysis was performed to examine the role of
HLA antibodies and cytomegalovirus mismatch on the development of
bronchiolitis obliterans syndrome and survival after lung transplanta-
tion. Methods: Of 339 consecutive lung transplantations performed over
a 102-month interval, 301 patients survived at least 3 months. There was
a minimum follow-up period of 13 months. Bronchiolitis obliterans syn-
drome was defined as a decline in forced expiratory volume in 1 second
less than 80% of posttransplantation baseline and/or histologic presence
of obliterative bronchiolitis and was defined as occurring “early” if doc-
umented within 3 years of transplantation. Variables analyzed included
preoperative donor and recipient cytomegalovirus status and the devel-
opment of antibodies to human leukocyte antigens after transplantation.
Microcytotoxicity was used to determine the presence of antibodies to
human leukocyte antigens. Variables were subjected to Kaplan-Meier
analysis to determine their impact on freedom from bronchiolitis oblit-
erans syndrome and survival. Results: The development of antibodies to
human leukocyte antigens after transplantation correlated significantly
with bronchiolitis obliterans syndrome (P = .02). The development of
antibodies to human leukocyte antigens did not affect survival (P = .33)
unless they were detected within 2 years of transplantation (P = .04).
There was greater frequency of early bronchiolitis obliterans syndrome
in cytomegalovirus seronegative patients who received allografts from
seropositive donors compared with all other combinations (P = .02).
There was also a trend toward worse survival of cytomegalovirus
seronegative patients who received allografts from seropositive donors
(P = .13). Conclusion: These data suggest that bronchiolitis obliterans
syndrome is the result of an immune-mediated process in which HLA
antibodies and cytomegalovirus may play a significant role. (J Thorac
Cardiovasc Surg 1998;116:812-20)
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T he most common cause of late morbidity and deathafter lung transplantation is bronchiolitis obliterans
syndrome (BOS).1,2 The cause of this chronic lung
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Previous investigators have identified several potential
risk factors for the development of BOS that include
frequent or severe early acute rejection,3-5 cyto-
megalovirus infection,6-10 class I human leukocyte
antigen (HLA) mismatches,10-13 and development of
antibodies to class I HLA.11 The prevalence of BOS has
been shown to exceed 50%.2 However, long-term fol-
low-up data regarding freedom from BOS are limited,
so the notion that this process is inevitable in all long-
term survivors of lung transplantation is controversial.
BOS frequently does not respond to medical therapy,
and the fibrosis resulting from obliterative bronchioli-
tis is irreversible once established. A more detailed
understanding of the pathogenesis of BOS may lead to
more effective prevention and treatment. This study
used Kaplan-Meier methods to analyze overall sur-
vival, the incidence of BOS, the effect of BOS on sur-
vival, and to further evaluate specific risk factors (cyto-
megalovirus mismatch and development of antibodies
to HLA) for the development of BOS.
Methods
Patient population. We retrospectively analyzed 339 con-
secutive lung transplantations performed at Barnes-Jewish
Hospital from August 1988 to December 1996. Three hun-
dred one patients survived at least 3 months after transplanta-
tion and form the basis of this analysis. The minimum follow-
up period was 13 months (median, 41 months). Operative
techniques14-16 and immunosuppression protocols17 have
been reported. Cytomegalovirus prophylaxis was used only
in recipients who were cytomegalovirus seronegative and
who received allografts from seropositive donors. From July
1989 to August 1991 (14 patients), prophylaxis was given in
the form of high-dose oral acyclovir or a 2- to 3-week course
of intravenous ganciclovir. After August 1991,
cytomegalovirus prophylaxis was given as a 16-week course
of intravenous ganciclovir.
Definition of BOS. The diagnosis of BOS was based on
pulmonary function data and histologic evidence from lung
biopsy results after transplantation with criteria established
by the 1993 International Society for Heart and Lung
Transplantation report.1 (1) Recipients were considered at
risk for BOS only if they survived 90 days after transplanta-
tion. (2) Recipients were determined to be free of BOS
(group 1) if their forced expiratory volume in 1 second
remained at 80% or more of their posttransplantation baseline
value and if there was no histologic evidence of obliterative
bronchiolitis. (3) Patients were defined as having BOS (group
2) if their forced expiratory volume in 1 second fell persis-
tently below 80% of their posttransplantation baseline value
and/or if obliterative bronchiolitis was documented histolog-
ically. (4) Patients were defined as having “early” BOS
(group 3) if the preceding BOS criteria were met within 3
years after transplantation. 
Before the diagnosis of BOS was applied, other specific
causes for declining pulmonary function (such as graft infec-
tion and bronchial anastomotic stricture) were ruled out.
Variables analyzed. The following variables were ana-
lyzed. (1) The effect of pre-operative cytomegalovirus mis-
match (patients who were cytomegalovirus seronegative and
who received allografts from donors who were
cytomegalovirus seropositive were compared with all other
combinations collectively [ie, cytomegalovirus seronegative
recipient and donor, cytomegalovirus seropositive recipient
and seronegative donor, cytomegalovirus seropositive recipi-
ent and donor]). (2) The presence of lymphocytotoxic HLA
antibodies was determined in the HLA laboratory with the
use of a panel of T and B lymphocytes from 36 random indi-
viduals of known–HLA type (panel reactive antibody test
[PRA]). The presence of HLA antibody was determined by
using the Amos-modified and antiglobulin-augmented micro-
cytotoxicity assays. The existence of HLA antibodies was
sought before transplantation and after transplantation. PRA
was considered positive before transplantation when there
was cytotoxicity to any cells in the panel. PRA was consid-
ered positive after transplantation when there was cytotoxicity
Table I. Demographic characteristics of lung allo-
graft recipients (n = 301)
Age (yr) 45 ± 12
Gender (n, %)
Male 146 (49)
Female 155 (51)
Primary disease
Chronic obstructive pulmonary disease 98 (33)
a l-Antitrypsin deficiency 54 (18)
Cystic fibrosis 47 (15)
Idiopathic pulmonary fibrosis 42 (14)
Primary pulmonary hypertension 35 (12)
Others 25 (8)
Transplant type (n, %)
Single lung 121 (40)
Bilateral single lung 178 (59)
Double lung 2 (1)
Data presented as mean ± standard deviation wherever possible
Table II. Cytomegalovirus (CMV) status and HLA
antibody development after transplantation and devel-
opment of BOS
Group I Group 2
(free of BOS; (with BOS;
Variable (n, %) n = 121) n = 180) Significance
CMVD+ to CMVR– 28 (23) 46 (26) P = .63
PRA– to PRA+ 14 (14)* 30 (19)† P = .12
PRA– to early PRA+ 9 (9) 20 (13) P = .32
Direct comparisons made by Fisher’s exact test.
*PRA data available in 100 patients.
†PRA data available in 158 patients.
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to 10% or more of the cells in the panel. Recipients in whom
cytotoxicity developed to 10% or more of the cells in the
panel within 2 years of transplantation were defined as hav-
ing early development of HLA antibodies.
Data analysis. The available data were first subjected to
direct comparisons between groups 1 and 2 and groups 1 and 3
with the Fisher’s exact test. Actuarial freedom from BOS and
actuarial survival were determined by the Kaplan-Meier
method18 and comparisons made with the Mantel-Haenszel test.
Results
Patient population and survival. Of 339 lung trans-
plantations, the 301 patients (89%) who survived at
least 3 months after the transplantation form the basis
of this study. The demographic and clinical data are
shown in Table I. The duration of survival was as fol-
lows: range, 3.9 to 104.8 months; mean, 43.6 months;
and median, 40.7 months.
Comparison of variables between groups. Sera
from both before and after transplantation were avail-
able (for determination of HLA antibody status) on 258
of the 301 patients evaluated (86%). The number of
posttransplantation serum samples varied from 1 to 34
per patient. These serum samples were obtained over
intervals ranging from 1 to 73 months after transplanta-
tion. Direct comparisons were made between
cytomegalovirus status and development of HLA anti-
bodies overall and within 2 years of transplantation
between each of the patient groups (Tables II and III).
There were trends toward greater proportions of
patients with cytomegalovirus-D+ to cytomegalovirus-
R– and the development of HLA antibodies in patients
with early BOS (group 3) compared with those patients
free of BOS (group 1), which did not reach significance.
Kaplan-Meier analysis. Overall survival of the study
population was 78%, 55%, and 38% at 3, 5, and 7 years
after lung transplantation, respectively (Fig 1, A).
Actuarial freedom from BOS was 42%, 25%, and 16%
over the same time intervals (Fig 1, B). Freedom from
BOS steadily declined over time so that no patient was
free of BOS at the latest follow-up interval (105
months; Fig 1, B). There was a trend toward worse late
survival for patients with BOS compared with those
patients without (Fig 2, A; P = .57). Because there
appeared to be a divergence in survival curves within
the first 3 years, we further stratified patients with BOS
into a subgroup in which BOS developed less than 3
years after transplantation (group 3). On the basis of this
stratification, we identified significantly worse sur-
vivals in patients who experienced early BOS onset
compared with those patients who did not (Fig 2, B; P
= .01). 
The development of HLA antibodies after transplan-
Fig 1. A, Actuarial survival scale for the 301 evaluable lung transplant recipients in this study. B, Actuarial free-
dom from BOS for the 298 evaluable lung transplant recipients in this study.
Table III. Cytomegalovirus (CMV) status and HLA
antibody development after transplantation and devel-
opment of BOS
Group 1 Group 3
(free of BOS) (with early BOS)
Variable (n, %) (n = 121)* (n = 146)† Significance
CMVD+ to CMVR– 28 (23) 44 (30) P = .08
PRA– to PRA+ 14 (14)* 26 (20)† P = .09
PRA– to early PRA+ 9 (9) 19 (15) P = .12
Direct comparisons made by Fisher’s exact test.
*PRA data available in 100 patients.
†PRA data available in 130 patients.
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tation correlated with the earlier development of BOS
(Fig 3, A; P = .02). The development of HLA antibod-
ies overall was not associated with significantly worse
survivals (Fig 3, B). Because the greatest impact of
antibody development on BOS appeared to be in the
first 24 months, we further stratified antibody produc-
ers into those patients in whom antibodies developed
within 2 years of transplantation and those patients in
whom development did not occur within 2 years of
transplantation. On this basis, there was a significant
association between the early development of HLA
antibodies and worse survivals (Fig 3, C; P = .04). 
Recipients who were cytomegalovirus seronegative
and who received allografts from seropositive donors
showed a trend toward greater development of BOS
overall (Fig 4, A; P = .16) and also early BOS (Fig 4,
B; P = .02). Cytomegalovirus mismatched patients also
showed a trend toward poorer survivals, which was not
significant (Fig 4, C; P = .13). 
Discussion
BOS remains the most significant long-term compli-
cation after lung transplantation.1,2 This chronic allo-
graft dysfunction is poorly understood, inadequately
treated, and, in most cases, fatal. In an attempt to con-
firm previous observations that development of BOS
correlates with poor survival,2 we looked at actuarial
survivals of lung transplant recipients who had BOS
compared with those who did not. Surprisingly, there
was no significant difference in long-term survival
between the 2 groups. In fact, at close examination, it
appears that the patients free of BOS actually fared
worse in terms of survival at follow-up periods of less
than 36 months (Fig 2, A). Examination of the cause of
death in these subjects with short follow-up periods
revealed many early deaths secondary to infection and
malignancy (data not shown), likely resulting from
immunosuppression. We therefore analyzed the effect
of development of BOS within 36 months of transplan-
tation on survivals and found that early BOS correlates
with decreased survival. This concurs with the findings
of Kroshus and associates13 who observed that greater
declines in cumulative survival were found in patients
in whom BOS developed early compared with those in
whom BOS developed later. This observation by this
laboratory and others13 that early development of BOS
correlates with earlier death after transplantation sup-
ports previous observations that development of BOS
is the most important limiting factor in the long-term
success of lung transplantation. In addition, this finding
implies that there may be certain markers that may her-
ald the onset of BOS and that their detection can allow
closer vigilance, new and earlier treatment methods,
and potential avoidance of BOS.
A previous retrospective analysis has shown that the
prevalence of BOS approaches and possibly exceeds
50% in long-term survivors.2 In the current report, with
a larger number of patients and longer follow-up time,
we observed a steady decline to zero in the proportion
of patients who were free of BOS. These discouraging
data suggest that the development of BOS is virtually
inevitable in all lung-transplant recipients who survive
long enough.
Previous investigators have identified and studied
several potential risk factors for the development of
BOS, including frequent or severe early acute rejec-
tion,3-5 cytomegalovirus infection,6-9 class I HLA mis-
Fig 2. A, Actuarial survival scale based on the presence (BOS+) or absence (BOS-) of BOS. B, Actuarial survival
scale based on the presence (Early BOS+) or absence (Early BOS–) of BOS onset within 3 years of the trans-
plantation.
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matches,10-13 and development of antibodies to class I
HLA.11
Cytomegalovirus has long been implicated as a risk
factor for the development of BOS and poor sur-
vival.6-10 Many investigators believe that the greatest
risk for cytomegalovirus-related complications after
lung transplantation lies with patients who are
cytomegalovirus seronegative and who receive allo-
grafts from donors who are cytomegalovirus seroposi-
tive.9 In this study, we found that this group of patients
was more likely to experience the development of BOS
within 3 years of transplantation. In addition, there was
a trend toward less favorable long-term survival in these
patients, which was not significant. The current data are
somewhat discrepant from our previous report that
showed no correlation between cytomegalovirus infec-
tion and the development of BOS.19 The apparent dis-
crepancy may be explained by the larger sample size,
longer follow-up period, and examination of patients
with early development of BOS as a separate group in
this study. Further study is needed to identify the true
risk of cytomegalovirus on the development of BOS.
The mechanism by which cytomegalovirus may play a
role in the development of BOS is speculative.
Associations between cytomegalovirus infection,
increased donor-specific alloreactivity, and the develop-
ment of BOS have been demonstrated.7 It has also been
shown that bronchoalveolar lavage, but not peripheral
blood lymphocytes, are capable of specific proliferation
to cytomegalovirus with an accumulation of cyto-
megalovirus-primed lymphocytes within the graft for
months.20 One potential mechanism for the association
Fig 3. A, Actuarial freedom from BOS based on the presence (Ab+) or absence (Ab–) of HLA antibodies devel-
oped after transplantation. B, Actuarial survival scale based on the presence (Ab+) or absence (Ab–) of HLA anti-
bodies developed after transplantation. C, Actuarial survival scale based on the presence (Early Ab+) or absence
(Early Ab–) of HLA antibodies developed within 2 years of the transplantation. 
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of cytomegalovirus infection with BOS is immunomod-
ulation of the graft milieu by inducing increased pro-
duction of inflammatory cytokines. This idea is sup-
ported by findings that cytomegalovirus can increase
expression of IFN-g , TNF-a , IL-4, and IL-6.21 It has
also been demonstrated that cytomegalovirus can
increase HLA class I and intercellular adhesion mole-
cule I expression on airway epithelial cells,22 thereby
making them more immunogenic.
In the present study we show that the development of
HLA antibodies correlates with earlier development of
BOS. Further, we determined that development of
HLA antibodies within 2 years of transplantation corre-
lated with less favorable survivals. The association
between chronic allograft rejection and the posttrans-
plantation development of HLA antibodies has been
made by this laboratory in lung transplantation11 and
by other investigators in heart23 and kidney24 trans-
plantation. Whether these antibodies are simply a
marker of the immune response or whether they play a
direct role in the development of chronic allograft
rejection is unclear. The finding that HLA-A locus mis-
matches have also been shown to correlate with the
development of BOS in lung transplant recipients11
makes it feasible that these antibodies are against donor
HLA and that they do play a direct role in the develop-
ment of chronic allograft rejection. Although acute cel-
lular rejection may be a TH1 response resulting in T-
lymphocyte activation, there may also be a TH2
response with subsequent B-lymphocyte activation and
Fig 4. A, Actuarial freedom from BOS based on the presence (CMV+) or absence (CMV–) of a patient who is
seronegative and who is receiving an allograft from a seropositive donor. B, Freedom from BOS within 3 years
of transplantation (Early BOS) based on the presence (CMV+) or absence (CMV–) of a patient who is seronega-
tive and who is receiving an allograft from a seropositive donor. C, Actuarial survival scale based on the pres-
ence (CMV+) or absence (CMV–) of a patient who is seronegative and who is receiving an allograft from a
seropositive donor. *Representative data at 36 months.
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alloantibody production. This laboratory has previously
shown that class I soluble HLA levels in bronchoalve-
olar lavage fluid from lung transplant recipients
increase during acute rejection.25 In addition, other
investigators have found elevated levels of soluble
HLA in the periphery of heart, liver, and kidney allo-
graft recipients.26 Therefore the source of antigen for
this alloantibody production may be soluble HLA in
the peripheral circulation and the allograft itself.
Recipients who share at least 1 class II HLA antigen
can participate in indirect antigen presentation by
donor epithelial cells. Although this seems feasible, to
date there is no evidence that epithelial cells with up-
regulated HLA class II expression can act as antigen-
presenting cells. It is more conceivable that indirect
alloantigen presentation by recipient macrophages
within the lung allograft may occur, leading to TH2
stimulation and subsequent alloantibody production.
The specific cascade of events that follow alloanti-
body production outside of hyperacute rejection is
speculative. Whether the antibodies remain in the cir-
culation in the form of immune complexes or bind to
the allograft leading to cytokine release and/or prolif-
eration of the bronchial epithelium and subepithelial
components of the airway walls is unknown. Saint
Martin and associates27 reported on 2 patients with fail-
ing pulmonary function early after transplantation that
responded to plasma exchange; however, subsequent
study failed to demonstrate antibody binding to allo-
graft tissue in a lung transplant population that includ-
ed patients with evidence of acute and chronic rejec-
tion. Failure to show antibody binding to any of the
lung allografts in this study could have resulted from
sampling error, lack of sensitivity of the test used to
detect the antibodies, and inadequate sample size of
patients with chronic rejection. Further investigation is
needed to determine whether alloantibodies bind to
lung allografts and what role they may play in the
development of BOS.
In summary, this study has demonstrated (1) the
development of BOS appears to be an inevitable long-
term complication of lung transplantation, (2) there is a
significant correlation between the development of
HLA antibodies on the development of BOS and poor
survival, and (3) there is a significant correlation
between unfavorable cytomegalovirus matching and
the development of early BOS.
We thank Mary S. Pohl, RN, BSN, MHS, and Tracey
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and Richard B. Schuessler, PhD, for his help with the statis-
tical analysis.
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Discussion
Dr R. Morton Bolman III (Minneapolis, Minn). The
Washington University group has made many contributions
to our understanding of lung transplantation and continue to
be leaders in our field. This report is a landmark study of the
risk factors and the prevalence of BOS after lung transplanta-
tion. Specifically, the investigation examines 2 risk factors:
cytomegalovirus donor-recipient mismatch and the develop-
ment of posttransplantation HLA antibodies and the subse-
quent development of BOS. 
Several interesting findings emerge. First, and most dis-
couraging, if followed long enough, BOS is likely to develop
in all recipients of lung allografts. Second, cytomegalovirus-
negative recipients of cytomegalovirus-positive donors expe-
rience a higher incidence of early BOS, occurring within 3
years of transplantation as defined by the authors. Third, the
development of posttransplant HLA antibodies portends ear-
lier development of BOS and, if it occurs in the first 2 years,
it is associated with decreased survival. All this confirms
what others have shown, namely, that BOS represents an
immunologic process consisting of some combination of
injury related to antigen-antibody deposition, cytokine
release, cell-mediated injury, and ultimately, fibrosis. 
We have also been interested in delineating the factors for
development of BOS after lung transplantation. Tim Kroshus
of our group published our data in The Journal of Thoracic
and Cardiovascular Surgery in August of 1997 (1997;114:
195-202). Somewhat in contrast to the study presented today,
we found cytomegalovirus pneumonitis, late acute rejection,
and HLA mismatch at the A locus to be statistical predictors
of BOS by multivariate analysis. Interestingly, asymptomatic
cytomegalovirus had no association with increased BOS in
our data. 
Furthermore, in our cohort, BOS was a statistical predictor
of worse survival regardless of when it appeared after trans-
plantation. Again, this is somewhat in contrast to your data. 
I have 3 questions. First, in the article you did not mention
the incidence of cytomegalovirus disease in the recipients. Is
there any correlation between cytomegalovirus disease,
rather than merely recipient-donor mismatch, and the subse-
quent development of BOS? 
Second, did you study the relationship of the incidence of
acute graft rejection to the development of BOS? Several
groups, including ours, have found a correlation between
these entities. 
Third, and I think most provocative, the incidence of
chronic rejection after lung transplantation is by far the high-
est of any solid-organ recipients. The notion of immunologic
markers for the development of BOS has been very intrigu-
ing to us, and Nancy Reinsmoen, formerly of our center,
developed the concept of donor antigen-specific hyporeactiv-
ity, which is a long phrase, that really tests for a specific
recipient’s reaction to his or her specific donor. Nancy devel-
oped a test for this and, in a small subpopulation of our trans-
plant recipients, found that those who at 1 year or later after
transplantation had no reaction to their donor did not experi-
ence obliterative bronchiolitis, at least up to 2 years. 
These data prompted us to consider modifying the immuno-
suppression of our patients based on these markers. Have you
considered any modification of immunosuppression based on
the data you showed, demonstrating that patients who experi-
ence the development of HLA antibodies, especially early after
transplantation, not only experience the development of BOS
earlier but also have a decreased survival?
Dr Smith. Let me start with the third question. At this time
we are investigating the mechanism by which HLA antibody
and/or cytomegalovirus leads to the development of BOS.
We have not made definitive steps toward using this infor-
mation clinically. At some point the data regarding develop-
ment of HLA antibodies may prove useful in treating patients
prophylactically for the development of BOS. However, cur-
rently patients are treated preemptively with increased
immunosuppression only when pulmonary function begins to
decline significantly. There are no other laboratory tests that
are being used at this time to identify these patients and make
decisions regarding the management of their conditions. 
To answer the questions regarding cytomegalovirus dis-
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ease, we only looked at mismatch status in these patients. The
Washington University Lung Transplant Group has previously
published an analysis of the relationship between cyto-
megalovirus pneumonitis and BOS, which showed that there
was no statistically significant difference in the development
of BOS between patients in whom cytomegalovirus pneu-
monitis developed and those in whom it did not. However,
that study analyzed a much smaller patient population with a
shorter follow-up period. At this point we have not looked at
cytomegalovirus disease in the current study population. It is
assumed, based on data from previous analyses, that patients
who are cytomegalovirus negative who receive allografts
from donors who are cytomegalovirus positive have a higher
incidence of cytomegalovirus-related complications. 
This study also did not analyze the incidence of acute
rejection and its effect on the development of BOS.
Dr Douglas J. Mathisen (Boston, Mass). In your analysis
of these patients, were there any patients who underwent
retransplantation, and if any, did you factor that into your sur-
vival analysis and did it have any impact on that? 
Dr Smith. There were only 6 patients who underwent
retransplantation of the 339 patients in the study. The survival
data in this study refer to survival of the allograft. Both
deaths and retransplantations were considered failures when
the Kaplan-Meier estimations were computed.
Dr Axel Haverich (Hannover, Germany). This is an impor-
tant yet not very optimistic study, because, like in all other
single-center series, the incidence of obliterative bronchioli-
tis is still very, very high. 
Maybe I missed it in your method section when you
described the way you assessed the HLA antibodies. Were
these antibodies always donor specific? I am asking this ques-
tion because there is a growing body of evidence that blood
transfusions at the time of transplantation in other solid organs
may have a significant impact on long-term graft survivals in
kidney transplantation, for instance; this is data from Germany.
So were those donor-specific HLA antibodies or not?
Do you have a way to assess obliterative bronchiolitis dur-
ing the entire course of this study? Was that a constant way,
did you perform biopsies all the time, or were the functional
parameters the constant factor over time? 
Dr Smith. The way that these antibodies were determined
in the sera was by panel-reactive antibody testing, which is a
microcytotoxicity analysis in which the sera is incubated with
a panel of T and B cells from normal individuals with known
HLA types in the presence of complement. The proportion of
lymphocytes within the panel that are lysed determines the
percent of the HLA types represented in the panel for which
the recipient has cytotoxic antibodies. This test does not
determine whether these antibodies are donor specific.
However, we do have a smaller group of patients that we
have analyzed for HLA antibodies determined by ELISA.
Using homozygous typing cells, we are seeing that these anti-
bodies are reactive to donor HLA. In addition, there is some
cross-reactivity with other HLA alleles.
To answer your second question, these patients are fol-
lowed with pulmonary function testing on a routine basis
throughout the posttransplantation period. In addition,
fiberoptic bronchoscopy is performed liberally in the imme-
diate postoperative period. Subsequently, surveillance bron-
choscopy with transbronchial biopsy is performed at 3 to 4
weeks, at around 3 months, at 1 year, and then annually there-
after. Patients will also undergo bronchoscopy whenever
there are clinical indications. There were few patients in
whom histologic obliterative bronchiolitis developed without
any evidence of a decline in pulmonary function.
